Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Korean Accounting Guidelines Aim For More Flexible Biopharma Practices

New Treatment Of R&D Costs

Executive Summary

South Korea moves to lay out clearer accounting guidelines related to R&D costs for pharma and biotech companies, making improvements to earlier official guidance in 2018 in order to ease uncertainties and help foster the sector.

You may also be interested in...



Korean Bioventure Financing Continues Downward Spiral In Q3

VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.

Korea Readying Itself For New Era Of Digital Therapeutics

Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.

New IO Progress For Korea's NeoImmuneTech, GI Innovation

While Chinese bioventures continue to surge ahead in immuno-oncology R&D, NeoImmuneTech says its long-acting human IL-7 in combination with pembrolizumab shows Phase IIa clinical efficacy in gastrointestinal tumors. Another Korean firm, GI Innovation, says its bispecific fusion protein/pembrolizumab combo shows synergistic effects in solid tumors at Phase I/II.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC147110

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel